Evidence map›Paper›PMID 34450519›Full record

ReviewCurrent opinion in virology2021

Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response.

Veronika I Zarnitsyna, Juliano Ferrari Gianlupi, Amit Hagar, T J Sego, James A Glazier

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Review
  7. Compositional modelling of immune response and virus transmission dynamics.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Veronika I ZarnitsynaDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.
Juliano Ferrari GianlupiDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA; Biocomplexity Institute, Indiana University, Bloomington, IN, USA.
Amit HagarDepartment of History and Philosophy of Science, Indiana University, Bloomington, IN, USA.
T J SegoDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA; Biocomplexity Institute, Indiana University, Bloomington, IN, USA.
James A GlazierDepartment of Intelligent Systems Engineering, Indiana University, Bloomington, IN, USA; Biocomplexity Institute, Indiana University, Bloomington, IN, USA. Electronic address: jaglazier@gmail.com.
Indiana University Bloomington · USEmory University · US

Funding

Multiscale modeling of influenza vaccination strategies for optimal T cell immunityU01HL139483 · NHLBI · EMORY UNIVERSITY · PI KOHLMEIER, JACOB E, ZARNITSYNA, VERONIKA I · 2018 to 2022
$3.5M
Competitive Renewal of Development, Improvement and Extension of the Tissue Simulation Environment - CompuCell3DR01GM122424 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI GLAZIER, JAMES ALEXANDER · 2017 to 2020
$1.7M
Dissemination of libRoadRunner and CompuCell3DU24EB028887 · NIBIB · UNIVERSITY OF WASHINGTON · PI GLAZIER, JAMES ALEXANDER, SAURO, HERBERT M. · 2019 to 2023
$1.5M
NHLBI NIH HHS U01 HL139483NIBIB NIH HHS U24 EB028887NIGMS NIH HHS R01 GM122424
6 · The paper itself

Abstract

The COVID-19 pandemic has highlighted a need for improved frameworks for drug discovery, repurposing, clinical trial design and therapy optimization and personalization. Mechanistic computational models can play an important role in developing these frameworks. We discuss how mechanistic models, which consider viral entry, replication in target cells, viral spread in the body, immune response, and the complex factors involved in tissue and organ damage and recovery, can clarify the mechanisms of humoral and cellular immune responses to the virus, viral distribution and replication in tissues, the origins of pathogenesis and patient-to-patient heterogeneity in responses. These models are already improving our understanding of the mechanisms of action of antivirals and immune modulators. We discuss how closer collaboration between the experimentalists, clinicians and modelers could result in more predictive models which may guide therapies for viral infections, improving survival and leading to faster and more complete recovery.

Indexed as

Computer SimulationCOVID-19 Drug TreatmentSARS-CoV-2COVID-19HumansHydrodynamicsIntersectoral Collaboration

Identifiers

PMID34450519
PMCPMC8384423
OpenAlexW3193727281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.